AstraZeneca is set to prioritize the treatment of early-stage cancers under the leadership of oncology research chief José Baselga. Talking to The Wall Street Journal, Baselga sketched out why he thinks splitting off from the congested pursuit of late-stage cancers will benefit AstraZeneca and patients.
